CN100345558C - Extract product of general flavone of kudzuvine root, preparation method and application - Google Patents

Extract product of general flavone of kudzuvine root, preparation method and application Download PDF

Info

Publication number
CN100345558C
CN100345558C CNB2005100412144A CN200510041214A CN100345558C CN 100345558 C CN100345558 C CN 100345558C CN B2005100412144 A CNB2005100412144 A CN B2005100412144A CN 200510041214 A CN200510041214 A CN 200510041214A CN 100345558 C CN100345558 C CN 100345558C
Authority
CN
China
Prior art keywords
extract
preparation
general flavone
kudzuvine root
alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CNB2005100412144A
Other languages
Chinese (zh)
Other versions
CN1726956A (en
Inventor
张朝波
张现涛
沈小钟
邵文豪
钱淑芸
贾树田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NANJING HAILING CHINESE MEDICINE PHARMACEUTICAL TECHNOLOGY RESEARCH Co Ltd
Original Assignee
NANJING HAILING CHINESE MEDICINE PHARMACEUTICAL TECHNOLOGY RESEARCH Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NANJING HAILING CHINESE MEDICINE PHARMACEUTICAL TECHNOLOGY RESEARCH Co Ltd filed Critical NANJING HAILING CHINESE MEDICINE PHARMACEUTICAL TECHNOLOGY RESEARCH Co Ltd
Priority to CNB2005100412144A priority Critical patent/CN100345558C/en
Publication of CN1726956A publication Critical patent/CN1726956A/en
Application granted granted Critical
Publication of CN100345558C publication Critical patent/CN100345558C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention provides an extract of total flavone of pueraria root and a preparation method thereof. The extract has a high content of total flavone. By the preparation method, the content of active components can be enhanced, and a large quantity of impurities is removed. Simultaneously, the preparation method has the advantages of good repeatability and stability, high obtainment rate of raw materials and low cost, and the preparation method is suitable for industrial production. The present invention also provides an application of the extract of total flavone of pueraria root in preparing medicines for treating cardio-cerebrovascular diseases. The preparation method of the extract of total flavone of pueraria root comprises the following preparation processes: pueraria root medicinal materials are extracted for 2 to 5 times by adding 30 to 90% alcohol solution with the volume 4 to 8 times greater than that of the pueraria root medicinal materials, and the extraction time is from 0.5 to 1.5 hours for each time; the extraction solution is concentrated and adsorbed by a macroporous adsorptive resin column; the extract is eluted with water for removing impurities, and then is eluted with 10 to 70% alcohol; the alcohol eluant is collected and concentrated, and then alcohol is added until the concentration of alcohol reaches 70 to 80%; deposits are filtered; filter liquor is concentrated; normal butyl alcohol is added for extraction; the normal butyl alcohol is recovered, and the liquor is concentrated and dried.

Description

Extract product of general flavone of kudzuvine root and its production and application
Technical field
The present invention relates to a kind of extract product of general flavone of kudzuvine root, and from the Chinese medicine Radix Puerariae, extract dosage form and the application on preparation treatment cardiovascular medicament such as the method for this Radix Puerariae total flavones and tablet, capsule or the injection of this extract, belong to field of medicaments.
Background technology
The cardiovascular diseases has been involved the whole world as " first killer " of harm humans health, is the main disaster of many rich countries.Although when the World War I, myocardial infarction is also rarely found as the major clinical types of coronary heart disease, and by 1940, coronary heart disease became the underlying cause of death of the U.S. and some industrialized country.Because the diagnosis of some type of coronary heart disease still has certain difficulty, thus represent cause of coronary heart disease and death with the M ﹠ M of acute myocardial infarction usually, wherein more commonly used with mortality rate.According to 11 national data that World Health Organization (WHO) announces nineteen ninety, the coronary heart disease death rate was the highest with Northern Ireland in 30~69 years old, and Finland takes second place, and Japan is minimum.Although before the mortality rate of U.S.'s coronary heart disease was than 30 years, descended 40%, but still occupied first of U.S.'s cause of the death.The data of the U.S. that NCHS in 1988 announces death toll in 1987 and cause of the death cis-position shows that heart disease accounts for 35% of total cause of the death, and wherein coronary heart disease death accounts for 24.1%, first of 10 causes of the death that rank forefront.Compared with developed countries, China still belongs to low country of coronary heart disease, but since the eighties, China's cardiovascular diseases's M ﹠ M is ascendant trend year by year.According to 1984 annual reports, coronary heart disease death is rough and careless: the city is 36.9/10 ten thousand, and the rural area is 15.6/10 ten thousand.1985~1989 years Monica schemes of Beijing's cardiopulmonary blood vessel center monitoring result shows that in 48 monitoring center by the WHO tissue, 35~64 years old coronary heart disease markization mortality rate of China only is higher than Japan, arranges second from the bottom.The males with coronary disease mortality rate is 49,/10 ten thousand, and the women is 27,/10 ten thousand, and the Finland higher with mortality rate (male 4,93/,100,000, and the women 63,/10 ten thousand) differs greatly.1986~nineteen ninety, China showed the perspective study result of 10 groups of crowd's hypertension, coronary heart disease, stroke onset and risk factors thereof, in monitoring 38 19659 man-years, 409 examples take place in acute myocardial infarction male altogether, the women is 200 examples, annual morbidity is respectively 10~26,/10 ten thousand, 8~13,/10 ten thousand; Mortality rate is respectively 4~11,/10 ten thousand and 2~5,/10 ten thousand.The coronary heart disease death number accounts for 4.47% (man) and 3 72 (woman) of total cause of the death.Had data to show in 96 years, the cardiovascular and cerebrovascular disease death toll has accounted for that total death toll is about 1/3, and wherein cerebrovascular accounts for 45%, and coronary heart disease accounts for 15%.Compare with western countries, the characteristics of China are that apoplexy is occurred frequently, and coronary heart disease is low to be sent out.At present, though it is a lot of to treat the medicine of cardiovascular and cerebrovascular disease in the world, owing to reasons such as the toxic and side effects of Western medicine and Chinese medicine drug effect are limited, the medicine that still needs to continually develop new high-efficiency low-toxicity satisfies broad masses of the people's healthy needs.
The Radix Puerariae beginning is stated from " herbal classic ", is legume pueraria lobata (Pueraria lobata (Willd.) Ohwi[P.thunbergiana (Sieb.et Zucc.) Benth.; P.hirsute (Thunb.) Schneid.; P.pseudo-hirsuta Tang er Wang]) or the tuber of Radix Puerariae rattan (Pueraria thomsonii Benth.).Cultivation or wild in hill shrubbery and sparse woods.Be distributed in ground such as Guangdong, Guangxi, Sichuan, Yunnan.Property is put down, sweet in the mouth, suffering.Return spleen, stomach warp.Main effect is an expelling pathogenic factors from muscles for reducing heat, delivers rash, promoting the production of body fluid to quench thirst, yang invigorating antidiarrheal.Cure mainly fever caused by exogenous pathogens, rigidity pain on the head and nape, measles goes out not smooth from the beginning of, rash, and epidemic febrile disease is thirsty, and diabetes is had loose bowels, dysentery, hypertension, coronary heart disease.The pharmacological action of Radix Puerariae and preparation thereof is more extensive, can singly use, but also compatibility becomes compound recipe to be used for the cerebrovascular treatment.The product that contains Radix Puerariae at present mostly is the Chinese medicine product greatly, and the prescription complexity is though the certain curative effect of tool exists also that dose is big, onset is slow, it is inconvenient to use, drug effect is limited and shortcoming such as quality control difficulty.
Radix Puerariae total flavones comprises puerarin (puerarin), daidzein (daidzein), and daidzins (daidzin) etc. are based on puerarin.The preparation method of traditional Radix Puerariae total flavones of bibliographical information has water extraction, alcohol extracting method, decoction and alcohol sedimentation technique, ethanol extract from water precipitation, because the complicated component of Radix Puerariae medical material, the composition that contains a lot of non-glycoside is so the content of the Radix Puerariae total flavones that traditional method for making obtains is generally lower.
Summary of the invention
The present invention is directed to present technology status, a kind of extract product of general flavone of kudzuvine root is provided, active constituent content height in this extract.
Another object of the present invention provides the preparation method of Radix Puerariae total flavones, and this method can improve the content of active component, removes a large amount of impurity, repeated simultaneously, good stability, and the yield height of raw material, and cost is low, is fit to suitability for industrialized production.
The present invention also provides the application of this extract product of general flavone of kudzuvine root.
For solving the problems of the technologies described above, the present invention has researched to developed following technical scheme.
A kind of extract product of general flavone of kudzuvine root is characterized in that the weight percentage of total flavones is at least 50% in the extract product of general flavone of kudzuvine root.
The weight percentage of total flavones is 50~95% in the above-mentioned extract product of general flavone of kudzuvine root.
The total flavones main active is puerarin and daidzein, and the weight percentage of puerarin and daidzein compositions is 40~85% in the described extract product of general flavone of kudzuvine root.
Any preparation that above-mentioned extract product of general flavone of kudzuvine root and pharmaceutically acceptable carrier and/or excipient are made.Described preparation can be tablet, capsule or injection.
The preparation method of above-mentioned extract product of general flavone of kudzuvine root, its preparation process is as follows:
Get the Radix Puerariae medical material, the alcoholic solution that adds 4~8 times of volumes 30~90% extracts 2-5 time, each 0.5-1.5 hour, extracting solution is concentrated upward macroporous adsorptive resins, first water eluting impurity, the ethanol elution of reuse 10~70%, collect ethanol elution, after concentrating, add ethanol and make determining alcohol reach 70-80%, the elimination precipitate, filtrate concentrates, add n-butanol extraction, reclaim n-butyl alcohol, concentrated, dry.
The macroporous resin model is D-101, DS-401 or AB-8 type in the above-mentioned preparation method; After the pulverizing medicinal materials, add 50% ethanol heat and carry twice, each 1h.
The application of above-mentioned extract product of general flavone of kudzuvine root in preparation treatment cardiovascular medicament.
The present invention has following advantage compared to existing technology:
The present invention uses the macroporous resin isolation technics, the abundant eluting of ethanol of reuse 10~50% behind upper prop, the water elution after adopting alcohol extract to concentrate, last reuse 95% ethanol, the purified method of n-butyl alcohol, obtain good effect, the method is not only easy and simple to handle, reduce cost, and very be fit to suitability for industrialized production.Studies show that in a large number D-101, DS-401 or AB-8 type macroporous resin are best to the adsorbing separation effect of Radix Puerariae total flavones.
Above-mentioned extract product of general flavone of kudzuvine root, its preparation of making meet the requirement of " medicine registration management way " Chinese medicine, natural drug registration classification 5, i.e. the preparation made of the effective site extracted of the Chinese medicine of listing, natural drug at home not.
The extract product of general flavone of kudzuvine root that said method makes, with pharmaceutically acceptable carrier and/or mixed with excipients, make according to a conventional method and contain the oral formulations that above-mentioned extract product of general flavone of kudzuvine root is a main active, as tablet, capsule, drop pill, soft capsule etc., and the preparation of the outer administration of gastrointestinal tract, as powder pin, injection etc.
In the extract product of general flavone of kudzuvine root that employing the present invention makes, content of total flavone is at least 50%, even can reach 50~95%, its main active is puerarin and daidzein, measure by high-efficient liquid phase technique, the content of puerarin and daidzein compositions can account for 40~85% of extract product of general flavone of kudzuvine root.Though except that mainly containing puerarin and daidzein, also contain compositions such as daidzin in the Radix Puerariae total flavones that the present invention extracts, this Radix Puerariae total flavones and contain the pharmaceutical composition of this Radix Puerariae total flavones curative effect is good generally.The pharmaceutical composition that pharmacodynamics test proves Radix Puerariae total flavones of the present invention and contains this Radix Puerariae total flavones has the effect of good treatment cardiovascular and cerebrovascular disease generally, compare with traditional preparation, the effective dose that the present invention treats cardiovascular and cerebrovascular disease is little, and toxic and side effects is little.
The present invention is owing to the macroporous adsorbent resin technology that has adopted in the modernization of Chinese medicine technology, the content of the active component in the extract product of general flavone of kudzuvine root is improved, improved curative effect, and removed a large amount of impurity, both solve the big problem of moisture absorption that Chinese patent medicine often has, reduced side effect again.
The preparation method of Radix Puerariae total flavones of the present invention has been done improvement on the basis of existing technology, deficiency at existing water extraction, alcohol extracting method, water extract-alcohol precipitation and macroporous resin adsorption separation method, and utilization macroporous adsorbent resin isolation technics, the abundant eluting of reuse 10~50% ethanol behind upper prop, the water elution after adopting alcohol extraction to concentrate, last reuse 95% ethanol, the purified method of n-butyl alcohol, obtained good effect, the method is not only easy and simple to handle, reduce cost, and very be fit to suitability for industrialized production.Studies show that in a large number D-101, DS-401 or AB-8 type macroporous resin are best to the adsorbing separation effect of Radix Puerariae total flavones.
The test of pesticide effectiveness:
Adopt several animal models to study the drug effect of the injection that extract product of general flavone of kudzuvine root of the present invention makes, and and main in the market treatment myocardial ischemia medicine Radix Salviae Miltiorrhizae Injection contrast, its test method and result are as follows:
1. pituitrin causes the rat heart muscle ischemia
40 of the normal SD rats of screening electrocardiogram, body weight 180-220g, ♀ ♂ half and half is divided into 5 groups at random.Model group, be subjected to 3 dosage groups of reagent and positive group.Successive administration ten days.First recording ecg (II leads) behind the last administration 30min then by rat sublingual vein injection of pituitrin 0.7u/kg, is observed, record gives behind the pituitrin 15,30,60, the electrocardiogram of rat during 90s, sees Fig. 1,2,3.Measure the T crest value, the results are shown in Table 1.
Table 1 extract product of general flavone of kudzuvine root is to the influence of rat ECG T wave peak value due to the pituitrin (Ban X Po ± SD)
Group Number of animals (only) Route of administration Dosage (g/kg) T crest value (mv)
Before giving Pit. To the increment (absolute value) behind the Pit.
30s 60s 90s
The heavy dose of group of dosage group extract product of general flavone of kudzuvine root in the model group Radix Salviae Miltiorrhizae Injection group extract product of general flavone of kudzuvine root small dose group extract product of general flavone of kudzuvine root 8 8 8 8 8 ip ip ip ip ip -
* compare with model group P<0.05 * * P<0.01
Experimental result shows: three dosage groups of extract product of general flavone of kudzuvine root of the present invention begin to reduce the T crest value after giving pituitrin 30s, with model group comparing difference remarkable (P<0.01).The prompting extract product of general flavone of kudzuvine root has significant protective effect to Acute Myocardial Ischemia in Rats due to the pituitrin.
2. isoproterenol causes the rat heart muscle ischemia
48 of screening electrocardiogram normal SD rats, body weight 180~220g, ♀ ♂ half and half is divided into six groups at random: blank group, model group, be subjected to 3 dosage groups of reagent and positive drug group.Each is organized and is administered once every day, continuous ten days.Rat electrocardiogram (II leads) respectively organized in record earlier before giving isoproterenol.Except that the blank group, all the other are respectively organized behind the 9th and the 10th day administration 30min, subcutaneous injection 8mg/kg isoproterenol, trace electrocardiogram behind the 30min, measure the degree of ST field offset, mv with the summation (∑ ST) of every group of ST field offset degree counts the index of ST average as the treating myocardial ischemia damage degree, the results are shown in Table 8.After last is given isoproterenol 2h, put to death rat, take out heart rapidly, weigh towards Xian with normal saline, put under 0~4 ℃ of condition, heart tissue is made 10% myocardium homogenate with interior cut Potter-Elvehjem Tissue Grinders, the centrifugal 15min of 3500rpm, get supernatant, measure myocardium CPK, LDH value, the results are shown in Table 2,3.
Table 2 extract product of general flavone of kudzuvine root is to the influence of rat heart muscle ischemia ECG ST field offset due to the isoproterenol (X ± SD)
Group Number of animals (only) Route of administration Dosage (g/kg) ST field offset (mv)
The heavy dose of group of dosage group extract product of general flavone of kudzuvine root in the model group injection of danshen group extract product of general flavone of kudzuvine root small dose group extract product of general flavone of kudzuvine root 8 8 8 8 8 ip ip ip ip ip - 0.5 0.25 0.75
Compare * P<0.05 * * P<0.01 with model group
Table 3 extract product of general flavone of kudzuvine root is to the influence of ischemic myocardium in rat CPK, LDH due to the isoproterenol (X ± SD)
Group Number of animals (only) Dosage (g/kg) CPK (u/l) LDH (u/l)
The heavy dose of group of dosage group extract product of general flavone of kudzuvine root in the blank group model group Diaoxinxue Kang group extract product of general flavone of kudzuvine root small dose group extract product of general flavone of kudzuvine root 8 8 8 8 8 8 - - 0.5 0.25 0.75 0.25
Compare * P<0.05 * * P<0.01 with model group
Compare ^^P<0.01 with blank
Experimental result shows: the ST field offset of extract product of general flavone of kudzuvine root three dosage groups is significantly less than model group (P<0.05,0.01); And CPK in the cardiac muscular tissue, LDH are increased, with model group comparing difference remarkable (P<0.05,0.01=.The prompting extract product of general flavone of kudzuvine root has significant protective effect to rat heart muscle ischemic injuries due to the isoproterenol.
3. other results of study of the applicant show: in myocardial ischemia experiment due to the anesthetized dog coronary ligation, the extract product of general flavone of kudzuvine root high dose group can reduce the DAP of myocardial infarction due to the anesthetized dog coronary ligation; Decreased heart rate; Extract product of general flavone of kudzuvine root height, middle dosage group can reduce myocardial infarction ∑-ST, N-ST due to the anesthetized dog coronary ligation, reduce due to the anesthetized dog coronary ligation after the myocardial infarction in the serum infarction size of myocardial infarction due to the release of CK, LDH and anesthetized dog coronary ligation, and have and reduce myocardial oxygen consumption trend, the prompting extract product of general flavone of kudzuvine root can obviously alleviate degree of myocardial ischemia, alleviates ischemia symptom.In the experiment of anesthetized dog hemodynamics, extract product of general flavone of kudzuvine root height, middle dosage group have hypotensive effect to DAP, the MAP of anesthetized dog tremulous pulse, and HR is had the effect of slowing down; The extract product of general flavone of kudzuvine root high dose group can increase anesthetized dog cardiac output (CO); Middle and high two dosage groups can increase anesthetized dog, anesthetized dog coronary flow (CBF); High dose group can obviously increase anesthetized dog anesthetized dog cardiac index (CI), stroke volume (SV) and dog SI (SI); The middle and high dosage group of extract product of general flavone of kudzuvine root reduces ejection time, total oxygen consumption (TTI) and blood vessel total peripheral resistance (TPVR).The prompting extract product of general flavone of kudzuvine root can reduce afterload, reduce cardiac work, cardiac function enhancing on the basis of not reducing the heart blood supply function, and myocardial ischemia is had protective effect.Dog blood pressure, electrocardiogram and heart rate are not all had obvious influence, and prompting this product does not have tangible adverse effect to cardiovascular system in the performance function of resisting myocardial ischemia.
In sum, extract product of general flavone of kudzuvine root has protective effect to acute myocardial ischemia, treating myocardial ischemia damage.
In addition, the present invention has overcome the defective of Chinese medicine traditional handicraft, macroporous adsorption resin technology in the utilization modernization of Chinese medicine technology, provide a kind of content height of knowing clearly, definite ingredients, quality controllable, curative effect really but, the preparation method of the little extract product of general flavone of kudzuvine root of side effect, the minimizing of the extract product of general flavone of kudzuvine root impurity of this method preparation not only can improve the moisture absorption that Chinese patent medicine often has, and make drug effect remarkable, reduce the side effect that some impurity causes, increase the compliance that the patient takes medicine, become a kind of modernized Chinese medicine of efficient, low toxicity.Preparation technology's repeatability of the present invention, stability are all good, and the yield height of raw material is fit to suitability for industrialized production.
Description of drawings
Fig. 1 is reference substance liquid chromatogram in the Radix Puerariae total flavones mensuration.
Fig. 2 is test sample liquid chromatogram in the Radix Puerariae total flavones mensuration of the present invention.
Specific implementation method
Among the embodiment, the Radix Puerariae medical material available from Huoshan county, Yuexi County, all meets " the regulation in 2005 editions one one of the Chinese pharmacopoeia under " Radix Puerariae " respectively.
The Radix Puerariae total flavones assay method: the photograph ultraviolet spectrophotometry (" 2005 editions appendix VA of Chinese pharmacopoeia) measure at 250nm wavelength place.
Puerarin assay method in the raw material: photograph high performance liquid chromatography HPLC (" 2005 editions appendix VID of Chinese pharmacopoeia) measure.
Chromatographic condition: with the octadecylsilane chemically bonded silica is filler; With methanol-water (25: 75) is mobile phase; The detection wavelength is 250nm.Number of theoretical plate calculates by puerarin peak should be not less than 4000.
The preparation of reference substance solution: precision takes by weighing puerarin reference substance 10mg, puts in the 25ml measuring bottle, adds 30% dissolve with ethanol and is diluted to scale, shakes up.Precision is measured 2ml, puts in the 10ml measuring bottle, adds 30% ethanol to scale, shakes up, promptly.
The preparation of medical material need testing solution: get the about 0.1g of Radix Puerariae medicinal powder (crossing sieve No. 3), the accurate title, decide, and puts in the conical flask, the accurate 30% ethanol 50ml that adds, claim to decide weight, reflux 30 minutes is put coldly, claims to decide weight again, subtract the weight of mistake with 30% ethanol deficiency, shake up filtration, get subsequent filtrate, promptly.
The preparation of extract need testing solution: precision takes by weighing extract 0.1g, puts in the 100ml measuring bottle, adds 30% dissolve with ethanol and is diluted to scale, shakes up.Precision is measured 2ml, puts in the 25ml measuring bottle, adds 30% ethanol to scale, shakes up, promptly.
Assay method: accurate respectively reference substance solution and each 10 μ l of need testing solution of drawing, inject chromatograph of liquid, measure, promptly get Fig. 1, Fig. 2.
The following example is intended to further describe the present invention, rather than limits the present invention by any way.
Embodiment 1:
Get the Radix Puerariae medical material (place of production: 100kg Huoshan County), be ground into coarse powder, put into extraction pot; Add 800L respectively, 800L concentration is that 50% ethanol heat is carried 2 times, each 1.5h, merge extractive liquid, filters, put cold, last D101 macroporous adsorptive resins, water fully be eluted to effluent for the clarification and do not have reducing sugar reaction after, the ethanol elution of reuse 30% is collected eluent, is evaporated to thick paste, add ethanol and make determining alcohol reach 80%, standing over night filters, filtrate concentrates, and adds n-butanol extraction, reclaims n-butyl alcohol, concentrated, dry, get Radix Puerariae extract 4.6kg.
Measure through the HPLC method: Radix Puerariae total flavones content is 65% in the above-mentioned experiment gained Radix Puerariae extract, and the main component puerarin content is 57% in the extract.
Embodiment 2:
Get the Radix Puerariae medical material (place of production: the Yuexi County) 100kg, be ground into coarse powder, put into extraction pot; Add 400L, 400L, 400L, 400L respectively, 400L concentration is that 30% ethanol heat is carried 5 times, each 0.5h, merge extractive liquid, filters, put cold, last DS-401 macroporous adsorptive resins, water fully be eluted to effluent for the clarification and do not have reducing sugar reaction after, the ethanol elution of reuse 30% is collected eluent, is evaporated to thick paste, add ethanol and make determining alcohol reach 70%, standing over night filters, filtrate concentrates, and adds n-butanol extraction, reclaims n-butyl alcohol, concentrated, dry, get Radix Puerariae extract 4.6kg.
Measure through the HPLC method: Radix Puerariae total flavones content is 77% in the above-mentioned experiment gained Radix Puerariae extract, and the main component puerarin content is 66% in the extract.
Embodiment 3:
Get the Radix Puerariae medical material (place of production: the Yuexi County) 100kg, be ground into coarse powder, put into extraction pot; Add 500L, 500L respectively, 500L concentration is that 90% ethanol heat is carried 3 times, each 1h, merge extractive liquid, filters, put cold, last AB-8 macroporous adsorptive resins, water fully be eluted to effluent for the clarification and do not have reducing sugar reaction after, the ethanol elution of reuse 30% is collected eluent, is evaporated to thick paste, add ethanol and make determining alcohol reach 75%, standing over night filters, filtrate concentrates, and adds n-butanol extraction, reclaims n-butyl alcohol, concentrated, dry, get Radix Puerariae extract 4.3kg.
Measure through the HPLC method: Radix Puerariae total flavones content is 65% in the above-mentioned experiment gained Radix Puerariae extract, and the main component puerarin content is 57% in the extract.
Embodiment 4
Get the Radix Puerariae medical material (place of production: 100kg Huoshan County), be ground into coarse powder, put into extraction pot; Add 800L, 600L, 600L respectively, 600L concentration is that 350% ethanol heat is carried 4 times, each 45min, merge extractive liquid, filters, put cold, last D101 macroporous adsorptive resins, water fully be eluted to effluent for the clarification and do not have reducing sugar reaction after, the ethanol elution of reuse 15% is collected eluent, is evaporated to thick paste, add ethanol and make determining alcohol reach 75%, standing over night filters, filtrate concentrates, and adds n-butanol extraction, reclaims n-butyl alcohol, concentrated, dry, get Radix Puerariae extract 4.7kg.
Measure through the HPLC method: Radix Puerariae total flavones content is 66% in the above-mentioned experiment gained Radix Puerariae extract, and the main component puerarin content is 57% in the extract.
Embodiment 5
Get the Radix Puerariae medical material (place of production: 100kg Huoshan County), be ground into coarse powder, put into extraction pot; Add 600L, 600L, 400L respectively, 400L concentration is that 80% ethanol heat is carried 4 times, each 50min, merge extractive liquid, filters, put cold, last D101 macroporous adsorptive resins, water fully be eluted to effluent for the clarification and do not have reducing sugar reaction after, the ethanol elution of reuse 60% is collected eluent, is evaporated to thick paste, add ethanol and make determining alcohol reach 75%, standing over night filters, filtrate concentrates, and adds n-butanol extraction, reclaims n-butyl alcohol, concentrated, dry, get Radix Puerariae extract 4.8kg.
Measure through the HPLC method: Radix Puerariae total flavones content is 67% in the above-mentioned experiment gained Radix Puerariae extract, and the main component puerarin content is 58% in the extract.
Embodiment 6:
The preparation of Radix Puerariae total flavones injection
Get embodiment 1 gained extract product of general flavone of kudzuvine root 200g, add the dissolving of an amount of water for injection after, add active carbon 0.02g again, heated and boiled 20 minutes filters, and adds water to 9L, NaOH with 1% transfers PH to 7~8, leaves standstill cold preservation, spend the night, filter, filtrate adds the injection water to 10L, (10ml/ props up in embedding, 20mg/ml), sterilization, promptly.Usage and dosage is every day 1 time, each 200~400mg intravenous injection or add the glucose solution iv drip of normal saline or 5%~10%.
Embodiment 7:
The capsular preparation method of Radix Puerariae total flavones:
Get embodiment 1 gained Radix Puerariae extract 500g, starch 250g, beta-schardinger dextrin-250g mixing is granulated, and sieves, and dresses up 3000 capsules (0.33g/ grain) after the drying, promptly.Usage and dosage: oral, each 3, every day 2 times.
Embodiment 8:
The preparation method of Radix Puerariae total flavones sheet:
Get embodiment 2 gained Radix Puerariae extract 500g, starch 250g, beta-schardinger dextrin-250g mixing is granulated, and sieves, and is pressed into 3000 (0.33g/ sheets) after the drying, promptly.Usage and dosage: oral, each 3, every day 2 times.

Claims (4)

1, a kind of injection is characterized in that this injection made by extract product of general flavone of kudzuvine root and pharmaceutically acceptable carrier and/or excipient, and wherein the weight percentage of total flavones is at least 50% in the extract product of general flavone of kudzuvine root; The total flavones main active is puerarin and daidzein, and the weight percentage of puerarin and daidzein compositions is 40-85%.
2, injection according to claim 1 is characterized in that the preparation process of extract product of general flavone of kudzuvine root is as follows:
Get the Radix Puerariae medical material, the alcoholic solution that adds 4-8 times of volume 30-90% extracts 2-5 time, each 0.5-1.5 hour, extracting solution is concentrated upward macroporous adsorptive resins, first water eluting impurity, the ethanol elution of reuse 10-70%, collect ethanol elution, after concentrating, add ethanol and make determining alcohol reach 70-80%, the elimination precipitate, filtrate concentrates, add n-butanol extraction, reclaim n-butyl alcohol, concentrated, dry.
3, injection according to claim 2 is characterized in that the macroporous resin model is D-101, DS-401 or AB-8 type.
4, injection according to claim 2, it is characterized in that pulverizing medicinal materials after, add 50% ethanol heat and carry twice, each 1h.
CNB2005100412144A 2005-07-27 2005-07-27 Extract product of general flavone of kudzuvine root, preparation method and application Active CN100345558C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2005100412144A CN100345558C (en) 2005-07-27 2005-07-27 Extract product of general flavone of kudzuvine root, preparation method and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2005100412144A CN100345558C (en) 2005-07-27 2005-07-27 Extract product of general flavone of kudzuvine root, preparation method and application

Publications (2)

Publication Number Publication Date
CN1726956A CN1726956A (en) 2006-02-01
CN100345558C true CN100345558C (en) 2007-10-31

Family

ID=35926595

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100412144A Active CN100345558C (en) 2005-07-27 2005-07-27 Extract product of general flavone of kudzuvine root, preparation method and application

Country Status (1)

Country Link
CN (1) CN100345558C (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102973643A (en) * 2012-12-14 2013-03-20 安徽珠峰生物科技有限公司 Extraction process of radix puerariae and measuring method of puerarin and total puerariae flavone
CN103039988A (en) * 2013-01-07 2013-04-17 湖南天盛生物科技有限公司 Production process for pueraria flavone functional water (drink)
CN104171503A (en) * 2014-07-03 2014-12-03 江西农业大学 Extraction method of total puerarin flavonoids and method for improving production performance of broiler chicken and quality of chicken meat by adopting total puerarin flavonoids
CN104561176A (en) * 2014-12-30 2015-04-29 绵阳劲柏生物科技有限责任公司 Method for preparing crude puerarin and crude daidzein through fermentation process
CN105079088A (en) * 2015-08-11 2015-11-25 成都易创思生物科技有限公司 Purifying method of puerariae total flavones
CN105168328A (en) * 2015-09-07 2015-12-23 宜诺(天津)医药工程有限公司 Kudzuvine root extract, extracting method and dropping pill of kudzuvine root extract
CN108014169A (en) * 2016-11-03 2018-05-11 西南大学 A kind of preparation method and applications of kudzu root extract and/or kudzu root flavone
CN107982310A (en) * 2017-11-16 2018-05-04 金华市飞凌生物科技有限公司 The preparation method of compound kudzu root flavones preparation
CN108159233A (en) * 2018-02-27 2018-06-15 柯金狮 A kind of Chinese medicine composition for treating diabetes and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1560062A (en) * 2004-03-11 2005-01-05 白栓锁 Process of extracting puerariae and making food and medicine addied with it

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1560062A (en) * 2004-03-11 2005-01-05 白栓锁 Process of extracting puerariae and making food and medicine addied with it

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
大孔树脂分离葛根总黄酮工艺优化 杨荣平,王宾豪,方艾权,寿清耀,中成药,第26卷第10期 2004 *

Also Published As

Publication number Publication date
CN1726956A (en) 2006-02-01

Similar Documents

Publication Publication Date Title
CN100345558C (en) Extract product of general flavone of kudzuvine root, preparation method and application
CN101045106A (en) Traditional Chinese medicine for treating lung heat cough and high fever
CN1857473A (en) Gynostemma pentaphylla saponin composition preparation and its preparing process
CN1285358C (en) Medicinal composition, preparation and quality control thereof
CN1814149A (en) Medicine composition for treating diabetes or diabetes kidney-disease, and preparing method
CN1706397A (en) Composition of paeoniflorin and peony lactone glycoside with function of increasing leukocyte
CN1895462A (en) Nankang soft capsule for treating prostatitis
CN1116868C (en) Concentrated granule medicine of famous decoction formulation and its preparation
CN1254252C (en) Medicine for treating ischemic angiocardiopathy and cerebrovascular disease and its preparation method
CN1193766C (en) Gardenia total glycoside composite for curing hepatitis and its preparation method
CN1233401C (en) Agastache capsule for restoring healthy energy andits prepn and application
CN1768770A (en) Quality control method of agavaceae extract medicinal formulation
CN1895495A (en) Hericiaceae contained Jianweiling capsules for stomach disease
CN1199683C (en) Medicine combination for reducing blood fat and preventing senescence and its medicines
CN1413656A (en) Weinakang for treating ischemic cerebrovascular disease and senile dementia and its preparation method
CN1836694A (en) Medicine composition for treating cardiovascular diseases and preparation method thereof
CN1176677C (en) Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and its preparing process
CN1634241A (en) Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process
CN1672722A (en) Heart-nourishing and tranquilizing medicine and its prepn process
CN1150918C (en) Medicine containing active components of Panax japonicum root and preparing process thereof
CN1772018A (en) Quality control method for speedwell flavone capsule
CN1861158A (en) Dispersing tablets of Liuwei-dihuang extract or its add-substract components, and its prepn. method
CN1733107A (en) Medicine for treating coronary disease and apoplexy sequelae and process for preparing the same
CN1939390A (en) Medicinal composition and its making method
CN1541690A (en) Chinese traditional medicine preparation Qimaishen for treating viral myocarditis and its manufacturing method

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant